Infliximab and the liver: abnormal biochemistry is common but don’t blame the drug
By Michael Woodhead
16 Mar 2020
A third of IBD patients taking infliximab have abnormal liver biochemistry but few have drug-induced liver injury directly caused by the TNF inhibitor, a Victorian study has found. With infliximab know to be associated with a risk of liver injury, clinicians at Eastern Health and Monash University in Melbourne investigated the liver enzymes (ALT and/or ...